Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 1

Conditions

Ovarian Neoplasms 32Breast Neoplasms 25Fallopian Tube Neoplasms 21Multiple Myeloma 18Carcinoma, Ovarian Epithelial 14Lymphoma 8Triple Negative Breast Neoplasms 4Recurrence 3Neoplasms, Plasma Cell 3Hodgkin Disease 3Prostatic Neoplasms 2Neoplasms 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Large B-Cell, Diffuse 2Leukemia 2Hematologic Neoplasms 2Burkitt Lymphoma 2Subcutaneous panniculitis-like T-cell lymphoma 1Solid Tumors 1Sarcoma, Synovial 1Sarcoma, Kaposi 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Peritoneal Neoplasms 1Patient Participation 1Pancreatic Neoplasms 1Osteosarcoma 1Neurofibrosarcoma 1

Interventions

Cyclophosphamide 15romidepsin 9Whole-Body Irradiation 9fludarabine phosphate 8Vincristine 8Etoposide 8Doxorubicin 8Prednisone 7Peripheral Blood Stem Cell Transplantation 7Mycophenolic Acid 7Brentuximab Vedotin 610-propargyl-10-deazaaminopterin 6Rituximab 5Granulocyte Colony-Stimulating Factor 5Gemcitabine 5Cyclosporine 5denileukin diftitox 4Nivolumab 4Lenalidomide 4mogamulizumab 3Tacrolimus 3Methotrexate 3Immunohistochemistry 3Gene Expression Profiling 3Dexamethasone 3Alemtuzumab 3selinexor 2pembrolizumab 2pegfilgrastim 2liposomal doxorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Lymphoma, T-Cell, Peripheral × liposomal doxorubicin × Clear all
NCT01445535 2021-11-03

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
15 enrolled 18 charts
DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

NCT00632827 2020-04-27

Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)

University of California, San Francisco

Phase 2 Terminated
21 enrolled 13 charts
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡